Synmosa Biopharma Stock Price To Earning
| 4114 Stock | TWD 33.60 0.10 0.30% |
Synmosa Biopharma fundamentals help investors to digest information that contributes to Synmosa Biopharma's financial success or failures. It also enables traders to predict the movement of Synmosa Stock. The fundamental analysis module provides a way to measure Synmosa Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Synmosa Biopharma stock.
Synmosa |
Synmosa Biopharma Company Price To Earning Analysis
Synmosa Biopharma's Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Current Synmosa Biopharma Price To Earning | 14.65 X |
Most of Synmosa Biopharma's fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Synmosa Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
| Competition |
Based on the latest financial disclosure, Synmosa Biopharma has a Price To Earning of 14.65 times. This is 43.3% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The price to earning for all Taiwan stocks is 48.99% higher than that of the company.
Synmosa Price To Earning Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Synmosa Biopharma's direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Synmosa Biopharma could also be used in its relative valuation, which is a method of valuing Synmosa Biopharma by comparing valuation metrics of similar companies.Synmosa Biopharma is rated below average in price to earning category among its peers.
Synmosa Fundamentals
| Return On Equity | 0.0894 | |||
| Return On Asset | 0.0223 | |||
| Profit Margin | 0.18 % | |||
| Operating Margin | 0.09 % | |||
| Current Valuation | 17.93 B | |||
| Shares Outstanding | 327.14 M | |||
| Shares Owned By Insiders | 25.42 % | |||
| Shares Owned By Institutions | 0.90 % | |||
| Price To Earning | 14.65 X | |||
| Price To Book | 3.09 X | |||
| Price To Sales | 4.06 X | |||
| Revenue | 3.23 B | |||
| Gross Profit | 1.29 B | |||
| EBITDA | 507.92 M | |||
| Net Income | 303.86 M | |||
| Cash And Equivalents | 1.28 B | |||
| Cash Per Share | 3.96 X | |||
| Total Debt | 2.27 B | |||
| Debt To Equity | 0.50 % | |||
| Current Ratio | 1.86 X | |||
| Book Value Per Share | 15.83 X | |||
| Cash Flow From Operations | 444.29 M | |||
| Earnings Per Share | 2.34 X | |||
| Target Price | 50.0 | |||
| Number Of Employees | 16 | |||
| Beta | 0.34 | |||
| Market Capitalization | 15.75 B | |||
| Total Asset | 10.32 B | |||
| Z Score | 3.6 | |||
| Annual Yield | 0.01 % | |||
| Five Year Return | 0.58 % | |||
| Net Asset | 10.32 B | |||
| Last Dividend Paid | 0.46 |
About Synmosa Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Synmosa Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Synmosa Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Synmosa Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Synmosa Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Synmosa Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Synmosa Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving together with Synmosa Stock
Moving against Synmosa Stock
| 0.92 | 2345 | Accton Technology Corp | PairCorr |
| 0.64 | 6674 | Compal Broadband Networks | PairCorr |
| 0.53 | 1796 | GeneFerm Biotechnology | PairCorr |
| 0.51 | 1795 | Lotus Pharmaceutical | PairCorr |
| 0.49 | 0050 | YuantaP shares Taiwan | PairCorr |
The ability to find closely correlated positions to Synmosa Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Synmosa Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Synmosa Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Synmosa Biopharma to buy it.
The correlation of Synmosa Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Synmosa Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Synmosa Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Synmosa Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Synmosa Stock Analysis
When running Synmosa Biopharma's price analysis, check to measure Synmosa Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Synmosa Biopharma is operating at the current time. Most of Synmosa Biopharma's value examination focuses on studying past and present price action to predict the probability of Synmosa Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Synmosa Biopharma's price. Additionally, you may evaluate how the addition of Synmosa Biopharma to your portfolios can decrease your overall portfolio volatility.